Stiripentol for focal refractory epilepsy.

Area of Science:

• Neurology
• Pharmacology

Background:

• Epilepsy affects many individuals, with nearly 30% experiencing uncontrolled seizures on current treatments.
• Stiripentol is a novel antiepileptic drug (AED) approved in Europe for Dravet syndrome.

Purpose of the Study:

• To assess the efficacy and tolerability of stiripentol as an add-on therapy for focal refractory epilepsy.
• To evaluate stiripentol's impact on seizure frequency, seizure freedom, and adverse events.

Main Methods:

• A systematic review of randomized controlled add-on trials of stiripentol was conducted.
• Searches included major databases (Cochrane, MEDLINE, EMBASE) and contact with the manufacturer and experts.
• One study involving 32 children with focal epilepsy was included, utilizing a responder-enriched design.

Main Results:

• No significant reduction in 50% seizure reduction or seizure freedom was observed with stiripentol compared to placebo.
• Add-on stiripentol was associated with a significantly higher risk of overall adverse effects.
• Wide confidence intervals for specific adverse events suggest potential increases in neurological and gastrointestinal issues.

Conclusions:

• The current evidence does not support the use of stiripentol as an add-on treatment for focal refractory epilepsy.
• Further large-scale, randomized, and well-conducted trials are necessary to establish stiripentol's role.